Dark

Check out our Dark Pool Levels

ETTX
Entasis Therapeutics Holdings Inc.
stock NASDAQ

Inactive

Jul 8, 2022

2.19USD-0.455%(-0.01)68,834

Pre-market

0.00USD-100.000%(-2.20)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 14, 2022

04:05PM EST Entasis Therapeutics Holdings Accepts Resignation Of Michael Gutch, CFO Benzinga

Jan 10, 2022

08:00AM EST Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022 GlobeNewswire Inc

Nov 24, 2021

01:48PM EST Entasis Therapeutics European Patent Office Patent Specification For Co.'s 'COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS' Benzinga

Nov 4, 2021

08:25AM EDT Entasis Therapeutics Hldg Q3 EPS $(0.26) Beats $(0.30) Estimate Benzinga

07:30AM EDT Entasis Therapeutics Announces Third Quarter 2021 Financial GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 28, 2021

08:00AM EDT Entasis Therapeutics to Report Third Quarter 2021 Results and Host GlobeNewswire Inc

Oct 20, 2021

08:02AM EDT BMO Capital Maintains Outperform on Entasis Therapeutics Hldg, Raises Price Target to $7 Benzinga

06:28AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.00 A.M. EDT). RTTNews

Oct 19, 2021

09:16AM EDT Zai Lab Highlights Data Out Of Its Partner, Entasis Therapeutics, Related To Topline Results From Sulbactam-Durlobactam Phase 3 ATTACK Trial Benzinga

09:00AM EDT SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients GlobeNewswire Inc

08:23AM EDT The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio Benzinga

07:20AM EDT HC Wainwright & Co. Maintains Buy on Entasis Therapeutics Hldg, Raises Price Target to $6 Benzinga

06:03AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.50 A.M. EDT). RTTNews

05:43AM EDT Entasis Therapeutics Shares Rise 23% Premarket; Co Announced Monday SUL-DUR Met Primary Endpoint Benzinga

Oct 18, 2021

04:10PM EDT Entasis Therapeutics Shares To Resume Trading At 4:35 p.m. ET Benzinga

04:07PM EDT Entasis Therapeutics Announces Topline Results From Phase 3 ATTACK Trial; SUL-DUR Met Primary Efficacy Endpoint Benzinga

04:05PM EDT Entasis Therapeutics announces positive topline results for GlobeNewswire Inc

Sep 23, 2021

04:14PM EDT Entasis Therapeutics To Participate In Cantor Global Healthcare Conference Thursday, Sept. 30 At 1:20 p.m. EDT Benzinga

04:05PM EDT Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021. GlobeNewswire Inc

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 15, 2021

04:01PM EDT Profile of Entasis Therapeutics ETX0462 Candidate Published in the GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Companys participation are as follows: GlobeNewswire Inc

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

04:22PM EDT Entasis Therapeutics Hldg Q2 EPS $(0.29) Beats $(0.32) Estimate Benzinga

04:05PM EDT Entasis Therapeutics Reports Second Quarter 2021 Financial Results GlobeNewswire Inc

Aug 10, 2021

08:00AM EDT Entasis Therapeutics to Host Expert Perspectives Webinar on GlobeNewswire Inc

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

04:05PM EDT Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021. GlobeNewswire Inc

Jul 27, 2021

11:13AM EDT Entasis Therapeutics And Zai Lab Complete Patient Enrollment In ATTACK Phase 3 Registrational Clinical Trial Of Sulbactam-Durlobactam Benzinga

11:13AM EDT Entasis Therapeutics, Zai Lab Report Completion Of Patient Enrollment In ATTACK Phase 3 Clinical Trail Of Sulbactam-Durlobactam Benzinga

Jul 14, 2021

08:00AM EDT Significant commercial strategy and product launch experience ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 GlobeNewswire Inc

Jul 1, 2021

08:03AM EDT Entasis Therapeutics Highlights Presentation Of ETX0462 Data At 2021 World Microbe Forum Benzinga

08:00AM EDT Entasis Therapeutics Introduces ETX0462, a First-in-Class GlobeNewswire Inc

Jun 18, 2021

01:48PM EDT Entasis Therapeutics Receives Intention to Grant a Patent from the European Patent Office Benzinga

08:01AM EDT Entasis Therapeutics Says Introduces First-In-Class Candidate ETX0462, Presents Data On SUL-DUR And ETX0282CPDP At Word Microbe Forum Benzinga

08:00AM EDT Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, GlobeNewswire Inc

May 5, 2021

04:33PM EDT Entasis Therapeutics Hldg Q1 EPS $(0.29) Up From $(1.15) YoY Benzinga

04:05PM EDT ATTACK Phase 3 topline data readout remains on track for second half of 2021 Strengthened balance sheet with $20M financing GlobeNewswire Inc

May 3, 2021

04:05PM EDT Entasis Therapeutics Completes Initial Closing of $20M Private GlobeNewswire Inc

Mar 23, 2021

08:00AM EDT Phase 3 ATTACK registration trial more than three-quarters complete ATTACK topline data readout expected second half of 2021 Zoliflodacin Phase 3 trial adds clinical trial sites, continues enrollment GlobeNewswire Inc

Jan 26, 2021

08:12AM EST Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program For Patients In The U.S. Benzinga

08:00AM EST Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded GlobeNewswire Inc

Jan 7, 2021

08:00AM EST Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. GlobeNewswire Inc

Nov 17, 2020

08:00AM EST Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.s Virtual Healthcare Symposium on Thursday, November 19th, 2020. GlobeNewswire Inc

Nov 6, 2020

09:48AM EST Entasis Therapeutics shares are trading lower after the company reported Q3 EPS results down from last year. Benzinga

Nov 5, 2020

04:57PM EST Entasis Therapeutics Hldg Q3 EPS $(0.37) Down From $(0.27) YoY Benzinga

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

08:52AM EDT Stocks Trading Near 52-Week Lows Before Open On Thursday, Oct. 29, 2020: WORX, OXY, HYLN, LXRX, TS, BTU, TCDA, GILD, ETTX, PBF, TEF, EURN Benzinga

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

Oct 14, 2020

08:00AM EDT Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020. GlobeNewswire Inc

Oct 5, 2020

04:34PM EDT Entasis Therapeutics S-3 Shows Registration From 18.7M Common Stock Offering Benzinga

Sep 10, 2020

08:00AM EDT Entasis Therapeutics to Participate in Upcoming Healthcare GlobeNewswire Inc

Sep 9, 2020

05:26AM EDT Cantor Fitzgerald Initiates Coverage On Entasis Therapeutics Hldg with Overweight Rating, Announces Price Target of $5 Benzinga

Aug 28, 2020

08:02AM EDT Entasis Therapeutics Announces $25M Private Placement Benzinga

Aug 6, 2020

05:21PM EDT Entasis Therapeutics Hldg Q2 EPS $(0.78) Up From $(1.02) YoY Benzinga

Aug 5, 2020

08:00AM EDT Entasis Therapeutics to Participate in Upcoming Healthcare Conferences GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 13, 2020

09:25AM EDT Roth Capital Initiates Coverage On Entasis Therapeutics Hldg with Buy Rating, Announces Price Target of $9 Benzinga

Share